From Lab to Patient - Revolutionizing Cell Therapy Manufacturing

Promoted on Potential...The Gender Gap No One Talks About

Why do young men get promoted on promise, while women have to prove themselves over and over? In this episode, we unpack the data behind one of the workplace’s most persistent double standards, the “potential vs. performance” bias. Drawing from McKinsey and LeanIn’s latest research, we explore how early-career promotions favor men, how bias shows up in performance reviews and leadership decisions, and why this gap hits women of color the hardest. You’ll hear what companies can do to break the cycle, how individuals can advocate for themselves and others, and why rethinking how we define leadership potential might be the key to closing the gender gap once and for all.

From Lab to Patient - Revolutionizing Cell Therapy Manufacturing

Cell therapy is one of the most promising frontiers in medicine — but scaling it remains a massive challenge. In this episode, we explore the complex landscape of cell therapy manufacturing, where automation is both a critical solution and a major stumbling block. From high capital costs and regulatory hurdles to the lack of interoperable systems and specialized talent, we break down why so few companies have cracked the code. Then we look at how Cellistic is changing that. With its integrated Pulse™ and Echo™ platforms built on iPSC (Induced Pluripotent Stem Cell) technology, Cellistic is offering an end-to-end solution for "off-the-shelf" allogeneic therapies that’s faster, more reliable, and potentially game-changing. We discuss how automation not only cuts costs and reduces errors, but also supports scalability, quality control, and regulatory readiness — if done right. Whether you’re navigating your own manufacturing strategy or just trying to understand the future of scalable cell therapy, this episode is for you. 🎙️ Topics Covered: * Why automation is so hard to implement in cell therapy * The gap between automation’s promise and actual adoption * How iPSCs unlock scalability for allogeneic therapies * What makes Cellistic’s Pulse™ and Echo™ platforms different * Real-world barriers (and enablers) of moving from benchtop to bedside Tune in to understand what’s standing in the way of cell therapy’s growth — and what’s finally pushing it forward.

Manufacturing drugs...... What? Like its hard?

Join me as I explore the unique and demanding challenges in pharmaceutical manufacturing, from stringent regulatory compliance and ensuring unwavering quality control to managing intricate global supply chains and integrating cutting-edge technologies. Discover why producing life-saving drugs is anything but simple

What’s the point of a placebo if we know it’s fake?

Tune in as we unravel the mysterious world of placebos and nocebos, exploring how your expectations can powerfully shape treatment outcomes, even with inert substances. We'll discuss their crucial role in double-blind clinical trials as the "gold standard" for validating treatments and delve into the complex ethical debates surrounding their use in both research and clinical practice.

Clinical trials - who, what, where, why, how?

Join us for a rapid dive into clinical trials, the "gold standard" of medical progress! These studies are fundamental to evaluating new treatments, generating crucial data on dosage, safety, and efficacy. We'll cover: * The Phases: From Phase 0 (exploratory, first-in-human) to Phase I (safety, dosage in 20-80 people), Phase II (preliminary efficacy, 100-300 people), and Phase III (confirmation, large scale, 1,000-3,000 people for regulatory approval). Phase IV continues post-market surveillance. * The Blueprint: Every trial follows a comprehensive protocol, its "operating manual," ensuring scientific validity, ethical compliance, and consistent data collection. * Ethical Pillars: Informed consent ensures participants understand and voluntarily agree to join, overseen by Institutional Review Boards (IRBs), which are independent ethics committees that review and approve studies to protect human subjects' rights and welfare. * Key Hurdles: Trials face significant challenges, including ethical and regulatory complexities, difficulties in patient recruitment, and limitations in budget and skilled staff. Tune in to understand why these meticulously conducted studies are essential for new health discoveries, acting as the rigorous proving ground where potential treatments are tested and refined before they can offer hope to millions.